Endocrine therapy trials for Metastatic Breast Cancer

All Endocrine therapy trials · All Metastatic Breast Cancer trials

Phase breakdown

Recruiting trials studying Endocrine therapy for Metastatic Breast Cancer

• A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
  NCT06369285 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 53 locations
• Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
  NCT07708194 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
  NCT05693766 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Implementing Geriatric Assessment for Dose Optimization of Cyclin-dependent Kinase (CDK) 4/6-inhibitors in Older Breast Cancer Patients
  NCT06044623 · Phase: Phase 3 · Ages: 70 Years and older · Sex: All (male and female) · 12 locations

Common questions

How many trials study Endocrine therapy for Metastatic Breast Cancer?

4 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.